Given the possibility that cimetidine may benefit a subset of patients without significant AEs in the context of a small total sample exposed to the drug (n=40, including the RCT), the lack of long-term follow-up data on sufficient numbers of patients, and its potential to interact with other drugs, oral cimetidine was designated as an Option
Key Takeaways An 8 to 6 Vote Against the Agencys Own Review The Pharmacy Compounding Advisory Committee met July 23 and 24 to review seven peptides
Current melanocortin agonists are addressing some of the issues encountered by previous failed agonists
It was developed by Metabolic Pharmaceuticals, an Australian biopharmaceutical company, in the late 1990s as a potential therapeutic for obesity and metabolic disorders
The peptide's signaling cascade engages within 20 to 40 minutes of injection, despite a plasma half-life of only 15 minutes
2026 Guide | Curex BCBS of Arizona covers Wegovy only where your employer opted in